Clinical Trials
6
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 50
- Registration Number
- NCT06980116
- Locations
- 🇪🇸
Hospital Fundación Jiménez Diaz, Madrid, Spain
🇪🇸Hospital Universitario HM Sanchinarro, Madrid, Spain
🇬🇧University Hospitals Plymouth NHS Trust, Plymouth, United Kingdom
Association of Ex Vivo Drug Response ( EVDR) and Clinical Outcome in Acute Myeloid Leukaemia (EXCYTE-2)
- Conditions
- Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML) Relapse
- First Posted Date
- 2024-10-18
- Last Posted Date
- 2025-08-26
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 91
- Registration Number
- NCT06648512
- Locations
- 🇦🇹
Medizinische Universität Graz, Graz, Austria
🇫🇮FHRB (Finnish Hematology Registry and Clinical Biobank), Vantaa, Finland
🇩🇪Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Klinik für Hämatologie und Onkologie, Berlin, Germany
Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
- Conditions
- Advanced Solid TumorHead and Neck Squamous Cell Carcinoma (HNSCC)Pancreatic AdenocarcinomaNon-small Cell Lung Cancer (NSCLC)Breast CarcinomaHigh-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC)Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma
- Interventions
- Drug: SoC
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2025-09-05
- Target Recruit Count
- 165
- Registration Number
- NCT05985655
- Locations
- 🇺🇸
START Midwest, Grand Rapids, Michigan, United States
🇺🇸START San Antonio, San Antonio, Texas, United States
🇺🇸START Mountain Region, West Valley City, Utah, United States
Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours
- First Posted Date
- 2023-06-27
- Last Posted Date
- 2023-11-08
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 6
- Registration Number
- NCT05920408
- Locations
- 🇧🇪
Institute Jules Bordet, Brussels, Belgium
🇧🇪CHU Mont-Godinne, Namur, Belgium
🇫🇷Institut Bergonie, Bordeaux, France
3-part Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of EXS21546
- Conditions
- Oncology
- Interventions
- Drug: EXS21546 Granule in CapsuleDrug: EXS21546 Powder for Oral SuspensionOther: MidazolamOther: Food EffectOther: Placebo Powder for Oral Suspension
- First Posted Date
- 2021-01-27
- Last Posted Date
- 2022-05-16
- Lead Sponsor
- Exscientia AI Limited
- Target Recruit Count
- 64
- Registration Number
- NCT04727138
- Locations
- 🇬🇧
Quotient Sciences, Nottingham, United Kingdom